Axogen, Inc. Appoints John H. Johnson to Board of Directors
July 19 2021 - 4:01PM
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for damage or discontinuity
to peripheral nerves, today announced that John H. Johnson has been
appointed to its Board of Directors, effective July 19, 2021.
Johnson will serve on both the Governance, Nominating and
Sustainability Committee and the Science and Technology Committee.
Johnson is a recognized leader in the biopharmaceutical industry
with more than 30 years of experience in senior leadership
positions, including at Johnson & Johnson, Eli Lilly &
Company, ImClone, and Centocor Ortho Biotech.
“John is an excellent addition to our board and brings a unique
breadth and depth of biopharmaceuticals experience in development
pipeline strategy and commercial execution,” commented Karen
Zaderej, chairman, CEO, and president. “John’s passion for pursuing
medical solutions that improve the lives of patients makes him a
natural fit for Axogen.”
Johnson currently serves as the CEO of Strongbridge Biopharma, a
company focused on building a portfolio of vertical,
therapeutically-aligned rare disease franchises. He previously
served as the CEO of Melinta Therapeutics, a commercial-stage
company developing and commercializing novel antibiotics, Dendreon
Corporation, Centocor Ortho Biotech, and ImClone. He also served as
President of Eli Lilly & Company’s Worldwide Oncology Unit and
as Company Group Chairman, Worldwide Biopharmaceuticals for Johnson
& Johnson. He currently serves on the board of directors of
Strongbridge Biopharma (NASDAQ: SBBP), Verastem Oncology (NASDAQ:
VSTM), and BioAgilytix (Private). He received his Bachelor of
Science degree from East Stroudsburg University of
Pennsylvania.
“I am honored to join the Axogen Board of Directors and work
with the company’s talented team to continue bringing forward
surgical solutions that address the unmet needs of an underserved
patient population,” said Johnson. “Axogen is a true innovator in
the industry and I look forward to supporting its ongoing work to
revolutionize the science of nerve repair.”
About AxogenAxogen (AXGN) is the
leading company focused specifically on the science, development,
and commercialization of technologies for peripheral nerve
regeneration and repair. Axogen employees are passionate about
helping to restore peripheral nerve function and quality of life to
patients with physical damage or transection to peripheral nerves
by providing innovative, clinically proven, and economically
effective repair solutions for surgeons and health care providers.
Peripheral nerves provide the pathways for both motor and sensory
signals throughout the body. Every day, people suffer traumatic
injuries or undergo surgical procedures that impact the function of
their peripheral nerves. Physical damage to a peripheral
nerve, or the inability to properly reconnect peripheral nerves,
can result in the loss of muscle or organ function, the loss of
sensory feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair features a
comprehensive portfolio of products, including Avance® Nerve Graft,
a biologically active off-the-shelf processed human nerve allograft
for bridging severed peripheral nerves without the comorbidities
associated with a second surgical site; Axoguard Nerve Connector®,
a porcine submucosa extracellular matrix (ECM) coaptation aid for
tensionless repair of severed peripheral nerves; Axoguard Nerve
Protector®, a porcine submucosa ECM product used to wrap and
protect damaged peripheral nerves and reinforce the nerve
reconstruction while preventing soft tissue attachments; and
Axoguard Nerve Cap®, a porcine submucosa ECM product used to
protect a peripheral nerve end and separate the nerve from the
surrounding environment to reduce the development of symptomatic or
painful neuroma. The Axogen portfolio of products is available in
the United States, Canada, the United Kingdom, South Korea, and
several other European and international countries.
Contact:Axogen, Inc.Peter Mariani, Executive Vice
President and Chief Financial
OfficerInvestorRelations@axogeninc.com
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Apr 2023 to Apr 2024